PCOS Is Now PMOS. A Step Forward, But Let's Not Pop the Champagne Yet
MMARA
Last updated:
May 14, 2026
Four women holding eachother, walking forward.
Four women holding eachother, walking forward.
An opinion piece
After more than a decade of advocacy, surveys, and global consensus-building, polycystic ovary syndrome has officially been renamed. Following input from tens of thousands of stakeholders over more than a decade1, PCOS is now polyendocrine metabolic ovarian syndrome — PMOS. And honestly? It's progress. Real progress. But if you've been dealing with hair loss tied to this condition, you probably know better than to celebrate a name change alone.
Let's give credit where it's due. The old name led many to believe they had large ovarian cysts, which most people with the condition do not actually have2. That misunderstanding had consequences. Delayed diagnoses, fragmented care, stigma, and missed opportunities for early intervention in metabolic and cardiovascular risks3, all of it, in part, tied to a name that didn't tell the truth about what was actually happening in the body.
The new name definitely does a better job. "Polyendocrine" recognizes the multiple interacting hormonal disturbances, including insulin, androgens, and neuroendocrine hormones, rather than treating this as an isolated ovarian disorder. "Metabolic" acknowledges features like insulin resistance and increased risks for type 2 diabetes and cardiovascular disease4.
For those of us in the hair loss community, that word androgens matters enormously. Androgen-driven hair thinning is a major source of psychological distress for women, and it's a well-known feature of this condition5, yet it has long been treated as a footnote rather than a central concern.
If you've been tracking your shedding, your cycle, and your hormone symptoms and still leaving appointments without answers, that's not a you problem. That's a systemic one. And it's exactly why tools like the MMARA app exist, to help you connect those dots yourself, build a timeline your provider can't ignore, and walk into every appointment with data, not just frustration.
Here's where my skepticism kicks in. A name is only as powerful as the research and clinical attention that follows it. The previous terminology obscured diverse endocrine and metabolic features and curtailed research and policy framing6, which means years of underfunding, underdiagnosis, and undertreated symptoms. Hair loss included. The question now isn't whether PMOS is a better name. It clearly is. The question is whether this renaming will translate into the research investment and clinical education that patients have been waiting decades for.
Up to 70% of those with the condition remain undiagnosed7. That's not a naming problem alone. That's a systemic failure that illustrates just how seriously this condition has not been taken. And for those experiencing hair loss as a symptom, the path to answers has been particularly frustrating. Hair loss gets dismissed, misattributed, or treated as cosmetic when it's anything but.
The renaming process was rigorous and inclusive, that deserves acknowledgment. More than 50 patient and professional organizations took part, and a three-year transition period is underway to support implementation8. That's the kind of structural follow-through that gives cautious optimism a foothold.
But we've seen promising shifts before. What people with PMOS-related hair loss need isn't just better terminology in a medical journal, they need providers who connect the dots between hormones, metabolism, and the hair on their head. They need research that treats hair loss as a clinical signal, not an aesthetic complaint.
PMOS is a step in the right direction. A meaningful one. But a step is still just a step. And at MMARA, we're not waiting around to see if the research catches up. Our mission has always been bigger than tracking hair loss. Every data point logged in our app is part of a larger vision: to contribute to the research that so many conditions, PMOS included, have been robbed of for decades. The women using MMARA aren't just managing their symptoms. They're helping build the evidence base that patients have always deserved.